• Canagliflozin Hemihydrate: Precision SGLT2 Inhibitor for Res

  2026-05-09

  Canagliflozin hemihydrate from APExBIO empowers high-fidelity glucose metabolism and diabetes mellitus research with rigorously validated SGLT2 inhibition. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights, ensuring robust, reproducible results in pathway-focused studies.

• O-GlcNAcylation Rewires Glycolysis for Wnt-Driven Bone Forma

  2026-05-08

  This study uncovers how Wnt signaling promotes bone formation by inducing O-GlcNAcylation, which stabilizes PDK1 and enhances aerobic glycolysis in osteoblasts. These mechanistic insights clarify the metabolic control underpinning osteogenesis and provide new avenues for metabolic intervention in bone biology.

• Berberine Hydrochloride: Bridging Gut-Bone and Metabolic Fro

  2026-05-08

  This thought-leadership article redefines the translational research landscape for Berberine hydrochloride by elucidating its dual impact on the gut-bone axis and metabolic regulation. Drawing on recent mechanistic insights and validated protocols, we highlight unique opportunities for translational teams to leverage Berberine hydrochloride as both a metabolic modulator and osteoimmune regulator. The discussion goes beyond standard product overviews, linking advanced mechanistic rationale, practical experimental guidance, and a clear outlook for clinical translation—anchored by APExBIO’s commitment to research excellence.

• CH 223191: Unraveling AhR Antagonism in Microbiota–Host Inte

  2026-05-07

  Explore how CH 223191, a potent aryl hydrocarbon receptor antagonist, empowers next-generation research into the microbiota–tryptophan–AhR axis and dioxin toxicity. This article reveals new insights into assay design and mechanistic discovery, surpassing traditional toxicology approaches.

• Protease Inhibitor Cocktail (EDTA-Free, 200X): Technical Gui

  2026-05-07

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) prevents protein degradation during extraction by inhibiting a broad spectrum of proteases without interfering with divalent cation-dependent assays. It is suitable for workflows like Western blotting, Co-IP, and phosphorylation studies, but should not be used where EDTA is required for metalloprotease inhibition.

• ISR Inhibition Prevents Forgetting and Reverses Epilepsy-Rel

  2026-05-06

  This study demonstrates that the integrated stress response (ISR) actively contributes to both natural and accelerated forgetting of established memories in mice. Pharmacological inhibition of the ISR using ISRIB (trans-isomer) prevented memory loss and reversed epilepsy-induced accelerated forgetting, suggesting a mechanistic link and translational potential for neurocognitive disorders.

• ZCL278: Precision Cdc42 Inhibition for Fibrosis and Neuronal

  2026-05-06

  Explore ZCL278, a selective Cdc42 inhibitor, as a cutting-edge tool for dissecting cell motility, neuronal branching, and fibrosis pathways. This article offers a unique analysis of ZCL278’s mechanistic and translational value, including protocol insights and reference-backed assay guidance.

• Lactate-Driven Epigenetic Immune Resistance in HCC: The H3K1

  2026-05-05

  This study uncovers how lactate-induced histone H3K18 lactylation (H3K18la) drives immune resistance in hepatocellular carcinoma (HCC) through activation of the KIF20A-c-Myc-PD-L1 pathway. Targeting glycolytic metabolism with inhibitors showed therapeutic synergy with anti-PD-1 immunotherapy, highlighting a novel, druggable metabolic-epigenetic axis with translational potential.

• Targeted SPP1 Inhibition in TAMs: A Path to Tumor Regression

  2026-05-05

  This article reviews recent evidence that small molecule inhibition of SPP1 in tumor-associated macrophages (TAMs) can significantly reduce tumor size, highlighting the reference study’s phenotypic screening and nanoformulation strategy. The findings offer a mechanistically distinct approach to reprogramming the tumor microenvironment, with implications for translational cancer immunotherapy.

• Targeted SPP1 Inhibition in Tumor-Associated Macrophages Red

  2026-05-04

  This study introduces a phenotypic screening approach to identify small molecule modulators that suppress SPP1 expression in tumor-associated macrophages, leading to reduced tumor size in murine models. The findings provide a technical foundation for precise TAM-targeted therapies and offer new directions for immunomodulatory cancer research.

• Applied Insights: Recombinant Human Growth Hormone in Cell A

  2026-05-04

  Leverage APExBIO's Recombinant Human Growth Hormone for robust, reproducible cell signaling and proliferation studies—now informed by landmark discoveries in IGFBP2-THBS1 axis regulation. This guide bridges practical protocol design with state-of-the-art molecular insights to empower next-generation growth hormone research.

• Cy5 hydrazide (non-sulfonated): Reliable Protein Carbonylati

  2026-05-03

  This article explores real-world laboratory scenarios where Cy5 hydrazide (non-sulfonated), SKU A8145, addresses persistent challenges in protein carbonylation labeling and oxidative stress detection. Through evidence-based Q&A, it demonstrates how this carbonyl-reactive fluorescent dye from APExBIO delivers reproducibility, sensitivity, and workflow adaptability essential for robust cell-based assays.

• Elobixibat Hydrate: Translational Insights for Precision GI

  2026-05-02

  Explore how Elobixibat hydrate, a leading ileal bile acid transporter inhibitor, uniquely informs translational assay design and clinical innovation for chronic idiopathic constipation. This in-depth analysis reveals evidence-based strategies and practical guidance beyond standard workflows.

• Transforming Senolytic Strategies: ABT-263 (Navitoclax) in T

  2026-05-01

  ABT-263 (Navitoclax) is redefining the landscape of cancer and senescence research through its targeted inhibition of Bcl-2 family proteins. This article dissects mechanistic insights, strategic workflows, and translational innovations, spotlighting new delivery paradigms—such as galactose-functionalized micelles—that elevate both efficacy and selectivity. Integrating recent peer-reviewed advances and best-practice protocol guidance, we provide actionable recommendations for researchers seeking to leverage apoptosis modulation in preclinical and clinical models of cancer and senescence.

• EZ Cap™ Firefly Luciferase mRNA: Cap 1 Reporter for Biolumin

  2026-05-01

  EZ Cap™ Firefly Luciferase mRNA offers enhanced translation and stability due to its Cap 1 structure and optimized poly(A) tail. This reagent delivers robust, reproducible bioluminescent signals, making it ideal for mRNA delivery, gene regulation, and in vivo imaging studies.

14756 records 1/984 page Next 12345 下5页 Last page